Stocky turns companies like Tandem Diabetes Care, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. TNDM's 16/100 Value Compounder Score reflects weak profitability and modest returns on invested capital, while the Vulnerable profile exposes structural headwinds in diabetes management devices—reimbursement pressure and commoditization risk in continuous glucose monitors. Leadership Alignment at 55/100 offers insufficient conviction to offset deteriorating economics.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Tandem Diabetes Care, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 21/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Tandem Diabetes Care, Inc. (TNDM) at 21/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. TNDM's 16/100 Value Compounder Score reflects weak profitability and modest returns on invested capital, while the Vulnerable profile exposes structural headwinds in diabetes management devices—reimbursement pressure and commodit
TNDM's current Stocky Verdict is 21/100, placing it in the "Avoid" band. This composite combines a 16/100 Compounder score, 55/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Tandem Diabetes Care, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Tandem Diabetes Care, Inc. scores 55/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Tandem Diabetes Care, Inc.'s Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Tandem Diabetes Care, Inc..
Sign up free and unlock the full analysis on TNDM — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for TNDM in the app.
